Sign Out
Pharmacology: Pharmacodynamics: Clinical Trials: Chronic Obstructive Pulmonary Disease: In an open-label, non-comparative, multi-center clinical study in 169 Filipino patients, Doxofylline (ANSIMAR) administered as 400 mg tablet twice daily for eight (8) weeks, was better tolerated by elderly COPD patients while providing the same effective bronchodilatory effect as other methylxanthine preparations.
The results of this study indicate that Doxofylline (ANSIMAR) is an effective and well-tolerated agent for Filipino patients with stable chronic obstructive pulmonary disease.
